PLoS One: 外泌体miR-9和miR-124与缺血性卒中相关

2016-10-30 MedSci MedSci原创

本研究的目的是检查急性缺血性卒中(AIS)患者血清中exosome的浓度及血清中exosome miR-9与miR-124,两个大脑的特定的miRNA水平变化在,并研究这些miRNA对AIS的诊断和损伤评估的预测价值。65例AIS急性期患者,66名非卒中志愿者作为对照组。应用Exoquick将血清exosome分离出外,通过透射电子显微镜,纳米粒子跟踪分析和免疫印迹进行验证。通过实时定量PCR测定

本研究的目的是检查急性缺血性卒中(AIS)患者血清中exosome的浓度及血清中exosome miR-9与miR-124,两个大脑的特定的miRNA水平变化在,并研究这些miRNA对AIS的诊断和损伤评估的预测价值。

65例AIS急性期患者,66名非卒中志愿者作为对照组。应用Exoquick将血清exosome分离出外,通过透射电子显微镜,纳米粒子跟踪分析和免疫印迹进行验证。通过实时定量PCR测定exosome中miR-9和miR-124。与对照组相比,AIS患者血清exosomes血清exosomal miR-9和miR-124的中位数水平均明显升高。miR-9和miR-124水平与美国国立卫生院卒中量表(NIHSS)评分,梗死体积和血清IL-6浓度呈正相关。miR-9和miR-124的曲线下的面积,分别为0.8026和0.6976。

研究表明血清exosomal miR-9和miR-124是AIS诊断和缺血性损伤的损伤程度的评估潜在标志物。然而,还需要进一步探索卒中后并发症中脑组织释放的外泌体的潜在作用。

原始出处:

Ji Q, Ji Y, et al. Increased Brain-Specific MiR-9 and MiR-124 in the Serum Exosomes of Acute Ischemic Stroke Patients. PLoS One. 2016 Sep 23.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1892806, encodeId=079b1892806c5, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Aug 15 02:20:00 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930433, encodeId=e6f619304333a, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Fri Dec 23 14:20:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789850, encodeId=99271e8985002, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun Mar 12 05:20:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806117, encodeId=0cfb180611e84, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Aug 18 15:20:00 CST 2017, time=2017-08-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1892806, encodeId=079b1892806c5, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Aug 15 02:20:00 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930433, encodeId=e6f619304333a, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Fri Dec 23 14:20:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789850, encodeId=99271e8985002, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun Mar 12 05:20:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806117, encodeId=0cfb180611e84, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Aug 18 15:20:00 CST 2017, time=2017-08-18, status=1, ipAttribution=)]
    2016-12-23 smallant2002
  3. [GetPortalCommentsPageByObjectIdResponse(id=1892806, encodeId=079b1892806c5, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Aug 15 02:20:00 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930433, encodeId=e6f619304333a, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Fri Dec 23 14:20:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789850, encodeId=99271e8985002, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun Mar 12 05:20:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806117, encodeId=0cfb180611e84, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Aug 18 15:20:00 CST 2017, time=2017-08-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1892806, encodeId=079b1892806c5, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Aug 15 02:20:00 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930433, encodeId=e6f619304333a, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Fri Dec 23 14:20:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789850, encodeId=99271e8985002, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun Mar 12 05:20:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806117, encodeId=0cfb180611e84, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Aug 18 15:20:00 CST 2017, time=2017-08-18, status=1, ipAttribution=)]

相关资讯

elife:癌细胞能够吃掉来自邻居的“问候”

(图片摘自www.sciencedaliy.com) "一开始我们的想法是癌细胞会通过与肿瘤微环境中的其它细胞交流而对自己的代谢机制进行调整"。来自莱斯大学生物分子与化学系的助理教授Nagrath说道。Nagrath教授等人最近在elife发表文章,揭示了细胞间传递的信号对癌细胞能量调节的影响。"这是我们从没想到的结果"。 该结果是Nagrath教授等人4年的研究成果,他的学生们以及来自其

Plos One:人类神经干细胞系源的外泌体miRNA内容物,化学计量法和转移的研究

外泌体是由多种细胞类型分泌的小胞膜囊泡(30-100nm),并且直到最近才作为细胞间沟通的新途径出现,它们是 RNA和蛋白质的天然运载体,使得它们作为一种有吸引力的潜在治疗性运载工具 miRNA是短链非编码 RNA ,可调节生物学过程,并且被发现存在于外泌体中,这里我们描述了来源于人类神经干细胞( hNSCs )的外泌体中的 miRNA ,我们选择的 hNSCs 系是克隆的,有条件限制的,永

外泌体:肿瘤发生与发展中的魔咒

肿瘤细胞已经发展出各种机制用于抵御药物作用,防止肿瘤从生物体中完全消失。其中一个被低估的就是高度特异、拥有双分子层结构的外泌体的作用。他们在局部微环境调节和细胞间通讯发挥了至关重要的作用。外泌体可以携带各种蛋白质,脂质,miRNAs与mRNA。现在有大量数据表明外泌体参与肿瘤进展和转移以及其影响。现也已经证实外泌体在多药耐药、放射诱导的旁观者效应、上皮间质化的作用。而且,外泌体能够形成转移前的

PNAS:干细胞释放的微囊泡有望更安全地治疗大脑放射损伤

已证实干细胞有望治疗癌症放疗导致的大脑区域损伤。在一项新的研究中,来自美国加州大学欧文分校的研究人员发现来自干细胞的微囊泡也提供类似的益处,同时不会产生利用干细胞治疗时产生的一些风险。相关研究结果于2016年4月4日在线发表在PNAS期刊上,论文标题为“Cranial grafting of stem cell-derived microvesicles improves cognition

Cancer Cell:外泌体携带长链非编码RNA传播肾癌细胞对靶向药物耐药

如果把传统的放化疗比作“万箭齐发、狂轰滥炸”,那么靶向治疗即为“精确制导、定点清除”。晚期肾癌患者希望实施靶向治疗,却一直缺乏标志物而“无靶可打”。第二军医大学长征医院泌尿外科王林辉课题组与东方肝胆外科医院生物信号转导实验室主任王红阳院士研究组合作,发现了一条介导肾癌靶向药物耐药形成的新型长链非编码RNA,可作为预测靶向药物治疗疗效的分子标志物和逆转靶向药物耐药的干预靶点,使晚期肾癌患者接受更加精

细胞外囊泡(细胞微粒、外泌体)检测新趋势

细胞外囊泡 细胞外囊泡(Extracellular Vesicles, EVs)是指从细胞膜上脱落或者由细胞分泌的双层膜结构的囊泡状小体,直径从40nm到1000nm不等。胞外囊泡主要由微囊泡(Microvesicles,  MVs)和外泌体(Exosomes, Exs)组成,微囊泡是细胞激活、损伤或凋亡后从细胞膜脱落的小囊泡,直径约为100nm – 1000nm。 外泌体由